Research graph
References from Intravaginal Delivery of Oxybutynin: An Alternative Administration Route to Improve its Pharmacokinetic and Pharmacodynamic Effects. Local targets link to admitted publications; unresolved targets remain external evidence.
Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: A systematic review and network meta-analysis
10.1016/j.euf.2021.08.011 · 2022 · External reference
Oxybutynin: past, present, and future
10.1007/s00192-012-1915-8 · 2013 · External reference
The pharmacokinetics of oxybutynin in man
10.1007/bf00558247 · 1988 · External reference
An update on the use of transdermal oxybutynin in the management of overactive bladder disorder
10.1177/1756287215626312 · 2016 · External reference
Transdermal oxybutynin
10.2165/00003495-200969030-00008 · 2009 · External reference
Treatments for overactive bladder: focus on pharmacotherapy
10.1016/s1701-2163(16)35440-8 · 2012 · External reference
Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms
10.1097/aog.0b013e31818e8aa4 · 2008 · External reference
Unresolved reference
External reference
Advances and future perspectives in epithelial drug delivery
10.1016/j.addr.2022.114293 · 2022 · External reference
Application of sol-gels for treatment of gynaecological conditions-physiological perspectives and emerging concepts in intravaginal drug delivery
10.3390/gels8020099 · 2022 · External reference
Non-invasive systemic drug delivery: developability considerations for alternate routes of administration
10.1002/jps.21793 · 2010 · External reference
Skin patch and vaginal ring versus combined oral contraceptives for contraception
10.1002/14651858.cd003552.pub2 · 2008 · External reference
The origins and evolution of ‘controlled’ drug delivery systems
10.1016/j.jconrel.2008.08.012 · 2008 · External reference
Controlled drug delivery systems: current status and future directions
10.3390/molecules26195905 · 2021 · External reference
Nanocarriers for vaginal drug delivery
10.2174/1872211313666190215141507 · 2019 · External reference
Why consider vaginal drug administration?
10.1016/j.fertnstert.2004.01.025 · 2004 · External reference
First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring
10.1080/10717544.2023.2180113 · 2023 · External reference
Exploring novel approaches to vaginal drug delivery
10.2174/187221111795471418 · 2011 · External reference
The vagina as a route for systemic drug delivery
10.1016/j.jconrel.2004.11.034 · 2005 · External reference
Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin
10.1016/s0168-3659(03)00277-3 · 2003 · External reference
Unresolved reference
2018 · External reference
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects
10.4065/78.6.696 · 2003 · External reference
Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment
10.1016/j.urology.2023.11.033 · 2024 · External reference
The cognitive effect of anticholinergics for patients with overactive bladder
10.1038/s41585-021-00504-x · 2021 · External reference
Overactive bladder and cognitive impairment: the American Urogynecologic Society and pelvic floor disorders research foundation state-of-the-science conference summary report
10.1097/spv.0000000000001272 · 2023 · External reference
Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride
10.1111/j.1532-5415.1998.tb01006.x · 1998 · External reference
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects
10.1016/j.eururo.2006.03.057 · 2006 · External reference
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study
10.1016/j.eururo.2013.01.002 · 2013 · External reference
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system
10.1177/00912700122010528 · 2001 · External reference
Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers
10.1007/bf00191165 · 1994 · External reference
Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects
10.1111/j.1365-2125.2011.03936.x · 2011 · External reference
Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system
10.1023/a:1022259011052 · 2003 · External reference
Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis
10.1007/s11255-019-02209-y · 2019 · External reference
The gynaecological examination—women’s experiences and preferences and the role of the gynaecologist
10.3109/01674828709023862 · 1987 · External reference
